311 related articles for article (PubMed ID: 35220945)
1. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
Wang R; Kang H; Zhang X; Nie Q; Wang H; Wang C; Zhou S
BMC Cancer; 2022 Feb; 22(1):214. PubMed ID: 35220945
[TBL] [Abstract][Full Text] [Related]
2. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
3. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
4. Urinary metabolomics for discovering metabolic biomarkers of laryngeal cancer using UPLC-QTOF/MS.
Chen J; Hou H; Chen H; Luo Y; Zhang L; Zhang Y; Liu H; Zhang F; Liu Y; Wang A; Hu Q
J Pharm Biomed Anal; 2019 Apr; 167():83-89. PubMed ID: 30759408
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics.
Jin X; Yun SJ; Jeong P; Kim IY; Kim WJ; Park S
Oncotarget; 2014 Mar; 5(6):1635-45. PubMed ID: 24721970
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer detection using targeted plasma metabolomics.
Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
[TBL] [Abstract][Full Text] [Related]
7. Serum metabolomics of end-stage renal disease patients with depression: potential biomarkers for diagnosis.
Yuan D; Kuan T; Ling H; Wang H; Feng L; Zhao Q; Li J; Ran J
Ren Fail; 2021 Dec; 43(1):1479-1491. PubMed ID: 34723750
[TBL] [Abstract][Full Text] [Related]
8. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
[TBL] [Abstract][Full Text] [Related]
9. Serum amino acid metabolic profiles of ankylosing spondylitis by targeted metabolomics analysis.
Zhou Y; Zhang X; Chen R; Han S; Liu Y; Liu X; Gao M; Yang C; Lu D; Sun B; Chen H
Clin Rheumatol; 2020 Aug; 39(8):2325-2336. PubMed ID: 32130577
[TBL] [Abstract][Full Text] [Related]
10. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
11. Plasma metabolic profiling analysis of cyclophosphamide-induced cardiotoxicity using metabolomics coupled with UPLC/Q-TOF-MS and ROC curve.
Yin J; Xie J; Guo X; Ju L; Li Y; Zhang Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1033-1034():428-435. PubMed ID: 27649503
[TBL] [Abstract][Full Text] [Related]
12. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
13. Untargeted metabolomics of bladder tissue using liquid chromatography and quadrupole time-of-flight mass spectrometry for cancer biomarker detection.
Nizioł J; Ossoliński K; Płaza-Altamer A; Kołodziej A; Ossolińska A; Ossoliński T; Krupa Z; Ruman T
J Pharm Biomed Anal; 2024 Mar; 240():115966. PubMed ID: 38217999
[TBL] [Abstract][Full Text] [Related]
14. LC-MS metabolomics of urine reveals distinct profiles for non-muscle-invasive and muscle-invasive bladder cancer.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Cana F; Herranz R; Pérez-Ardavín J; Vera-Donoso CD; Martínez-Sarmiento M; Medina P
World J Urol; 2022 Oct; 40(10):2387-2398. PubMed ID: 36057894
[TBL] [Abstract][Full Text] [Related]
15. Metabolic signatures of osteoarthritis in urine using liquid chromatography-high resolution tandem mass spectrometry.
Abdelrazig S; Ortori CA; Doherty M; Valdes AM; Chapman V; Barrett DA
Metabolomics; 2021 Mar; 17(3):29. PubMed ID: 33655418
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
17. Targeted and untargeted urinary metabolic profiling of bladder cancer.
Ossoliński K; Ruman T; Copié V; Tripet BP; Kołodziej A; Płaza-Altamer A; Ossolińska A; Ossoliński T; Nieczaj A; Nizioł J
J Pharm Biomed Anal; 2023 Sep; 233():115473. PubMed ID: 37229797
[TBL] [Abstract][Full Text] [Related]
18. Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers.
Chen YT; Huang HC; Hsieh YJ; Fu SH; Li L; Chen CL; Chu LJ; Yu JS
J Food Drug Anal; 2019 Apr; 27(2):460-474. PubMed ID: 30987717
[TBL] [Abstract][Full Text] [Related]
19. A urinary metabolomic study from subjects after long-term occupational exposure to low concentration acrylamide using UPLC-QTOF/MS.
Wang SY; Han D; Pan YL; Yu CP; Zhou XR; Xin R; Wang R; Ma WW; Wang C; Wu YH
Arch Biochem Biophys; 2020 Mar; 681():108279. PubMed ID: 31982394
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of Clostridium difficile infection using an UPLC-MS based metabolomics method.
Zhou P; Zhou N; Shao L; Li J; Liu S; Meng X; Duan J; Xiong X; Huang X; Chen Y; Fan X; Zheng Y; Ma S; Li C; Wu A
Metabolomics; 2018 Jul; 14(8):102. PubMed ID: 30830376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
